^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
multi-target gene-modified CAR-T/TCR-T cell immunotherapy
i
Other names: multi-target gene-modified CAR-T/TCR-T cell immunotherapy
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Shenzhen BinDeBio
Drug class:
CD19-targeted CAR-T immunotherapy, BCMA-targeted CAR-T immunotherapy, Mesothelin-targeted CAR-T immunotherapy, CD22-targeted CAR-T immunotherapy, EGFRvIII-targeted CAR-T immunotherapy, c-MET-targeted CAR-T immunotherapy, CD33-targeted CAR-T immunotherapy, DR5-targeted CAR-T immunotherapy, NY ESO 1-targeted CAR-T immunotherapy
Related drugs:
over3years
Autologous CAR-T/TCR-T Cell Immunotherapy for Solid Malignancies (clinicaltrials.gov)
P1/2, N=50, Recruiting, Shenzhen BinDeBio Ltd. | Trial completion date: Dec 2020 --> Dec 2021 | Trial primary completion date: Dec 2020 --> May 2021
Trial completion date • Trial primary completion date
|
HLA-A (Major Histocompatibility Complex, Class I, A) • MSLN (Mesothelin) • CTAG1B (Cancer/testis antigen 1B)
|
MSLN positive • HLA-A positive
|
multi-target gene-modified CAR-T/TCR-T cell immunotherapy
Share via
